Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Child's Nervous System
Published in: Child's Nervous System 4/2007

01-04-2007 | Original Paper

Pilot study of ifosfamide/carboplatin/etoposide (ICE) for peripheral blood stem cell mobilization in patients with high-risk or relapsed medulloblastoma

Authors: Shuichi Okada, Teruaki Hongo, Kimiyoshi Sakaguchi, Kazunori Suzuki, Shigeru Nishizawa, Takehiko Ohzeki

Published in: Child's Nervous System | Issue 4/2007

Login to get access

Abstract

Objectives

The purpose of this study is to evaluate the stem cell mobilization capacity, anti-tumor effect, and feasibility of ifosfamide/carboplatin/etoposide (ICE) for transplant-eligible patients with medulloblastoma.

Materials and methods

Six patients (23 months to 18 years old) with high-risk or relapsed medulloblastoma received one cycle of ICE, which consisted of ifosfamide at 1.8 g/m2 for 5 days, carboplatin 400 mg/m2 for 2 days, and etoposide 100 mg/m2 for 5 days. Stem cells were mobilized with ICE followed by granulocyte colony-stimulating factor at 10 μg kg−1 day−1.

Results

After one cycle of ICE, the median number of harvested CD34+ cells per apheresis session was 11.85 × 106 cells/kg (range, 0.2 to 71.2 × 106 cells/kg). Two patients obtained a complete response and three patients a partial response. All patients experienced severe myelosuppression, and three infectious toxicities were observed.

Conclusions

These results suggest that ICE is optimal for mobilizing stem cells, effective for high-risk or relapsed medulloblastoma, and tolerable with limited non-hematological toxicity.
Literature
1.
Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, Lucraft H, Gilbertson R, Tait DM, Walker DA, Pizer BL, Imeson J, Lashford LS (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 study. J Clin Oncol 21:1581–1591PubMedCrossRef
2.
Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, Allen JC, Stevens KR, Stanley P, Li H, Wisoff JH, Geyer JR, McGuire-Cullen P, Stehbens JA, Shurin SB, Packer RJ (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 17:832–845PubMed
3.
Packer RJ, Goldwein J, Nicholson HS, Vezina LG, Allen JC, Ris MD, Muraszko K, Rorke LB, Wara WM, Cohen BH, Boyett JM (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group study. J Clin Oncol 17:2127–2136PubMed
4.
Taylor RE, Bailey CC, Robinson KJ, Weston CL, Walker DA, Ellison D, Ironside J, Pizer BL, Lashford LS (2005) Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 41:727–734PubMedCrossRef
5.
Rood BR, Macdonald TJ, Packer RJ (2004) Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 31:666–675PubMedCrossRef
6.
Gardner SL (2004) Application of stem cell transplant for brain tumors. Pediatr Transplant 8(Suppl 5):28–32PubMedCrossRef
7.
Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH (2003) Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol 14(Suppl 1):i5–i10PubMedCrossRef
8.
Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O’Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD (1999) Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol 17:3776–3785PubMed
9.
Abu-Ghosh AM, Krailo MD, Goldman SC, Slack RS, Davenport V, Morris E, Laver JH, Reaman GH, Cairo MS (2002) Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms’ tumor: a Children’s Cancer Group report. Ann Oncol 13:460–469PubMedCrossRef
10.
Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G, Cairo MS (2005) Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience. Pediatr Blood Cancer 44:338–347PubMedCrossRef
11.
López-Aguilar E, Sepúlveda-Vildósola AC, Rivera-Márquez H, Cerecedo-Diaz F, Valdes-Sanchez M, Delgado-Huerta S, Wanzke-del Angel V, Ramon-Garcia G, Rodriguez-Jimenez H, Hernandez-Contreras I, Santacruz-Castillo E, Romo-Rubio HA (2003) Preirradiation ifosfamide, carboplatin and etoposide (ICE) for the treatment of high-grade astrocytomas in children. Childs Nerv Syst 19:818–823PubMedCrossRef
12.
Sanson M, Ameri A, Monjour A, Sahmoud T, Ronchin P, Poisson M, Delattre JY (1996) Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Eur J Cancer 32A:2229–2235PubMedCrossRef
13.
Loss JF, Santos PP, Leone LD, Brunetto AL (2004) Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): a phase II study in a pediatric oncology centre in Brazil. Pediatr Blood Cancer 42:139–144PubMedCrossRef
14.
Kung FH, Desai SJ, Dickerman JD, Goorin AM, Harris MB, Inoue S, Krischer JP, Murphy SB, Pratt CB, Toledano S (1995) Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol 17:265–269PubMedCrossRef
15.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRef
16.
Fruehauf S, Seggewiss R (2003) It’s moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement. Br J Haematol 122:360–375PubMedCrossRef
17.
Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C (2000) Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 18:1360–1377PubMed
18.
Sezer O, Possinger K, Metzner B, Illiger HJ, Wattad M, Heit W, Fuss H, Schultze W (2000) Optimal CD34 (+) cell dose in autologous peripheral-blood stem-cell transplantation. J Clin Oncol 18:3319–3320PubMed
19.
Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD (1990) Carboplatin in childhood brain tumors. A Children’s Cancer Study Group Phase II trial. Cancer 66:2465–2469PubMedCrossRef
20.
Mastrangelo R, Lasorella A, Riccardi R, Colosimo C, Iavarone A, Tornesello A, Mastrangelo S, Ausili-Cefaro G, Di Rocco C (1995) Carboplatin in childhood medulloblastoma/PNET: feasibility of an in vivo sensitivity test in an “up-front” study. Med Pediatr Oncol 24:188–196PubMedCrossRef
21.
Boor R, Huber A, Gutjahr P (1994) Etoposide treatment in recurrent medulloblastoma. Neuropediatrics 25:39–41PubMedCrossRef
22.
Kobrinsky NL, Packer RJ, Boyett JM, Stanley P, Shiminski-Maher T, Allen JC, Garvin JH (1999) Etoposide with or without mannitol for the treatment of recurrent or primarily unresponsive brain tumors: a Children’s Cancer Group study, CCG-9881. J Neurooncol 45:47–54PubMedCrossRef
23.
Chastagner P, Sommelet-Olive D, Kalifa C, Brunat-Mentigny M, Zucker JM, Demeocq F, Baranzelli MC, Tron P, Bergeron C, Pein F (1993) Phase II study of ifosfamide in childhood brain tumors: a report by the French Society of Pediatric Oncology (SFOP). Med Pediatr Oncol 21:49–53PubMedCrossRef
24.
Heideman RL, Kovnar EH, Kellie SJ, Douglass EC, Gajjar AJ, Walter AW, Langston JA, Jenkins JJ, Li Y, Greenwald C (1995) Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors. J Clin Oncol 13:2247–2254PubMed
25.
López-Aguilar E, Sepúlveda-Vildósola AC, Rivera-Márquez H, Cerecedo-Diaz F, Santacruz-Castillo E, Valdez-Sanchez M, Arias-Gomez J, Quintana-Roldan G (1998) Survival of patients with medulloblastoma treated with carboplatin and etoposide before and after radiotherapy. Arch Med Res 29:313–317PubMed
26.
Kortmann RD, Kühl J, Timmermann B, Mittler U, Urban C, Budach V, Richter E, Willich N, Flentje M, Berthold F, Slavc I, Wolff J, Meisner C, Wiestler O, Sorensen N, Warmuth-Metz M, Bamberg M (2000) Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT ’91. Int J Radiat Oncol Biol Phys 46:269–279PubMedCrossRef
27.
Kühl J, Müller HL, Berthold F, Kortmann RD, Deinlein F, Maass E, Graf N, Gnekow A, Scheurlen W, Gobel U, Wolff JE, Bamberg M, Kaatsch P, Kleihues P, Rating D, Sorensen N, Wiestler OD (1998) Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT’88/’89. Klin Pädiatr 210:227–233PubMed
28.
Gajjar A, Kühl J, Epelman S, Bailey C, Allen J (1999) Chemotherapy of medulloblastoma. Childs Nerv Syst 15:554–562PubMedCrossRef
29.
Gerke P, Filejski W, Robins HI, Wiedemann GJ, Steinhoff J (2000) Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant-heat-induced whole-body hyperthermia. J Cancer Res Clin Oncol 126:173–177PubMedCrossRef
30.
Metadata
Title
Pilot study of ifosfamide/carboplatin/etoposide (ICE) for peripheral blood stem cell mobilization in patients with high-risk or relapsed medulloblastoma
Authors
Shuichi Okada
Teruaki Hongo
Kimiyoshi Sakaguchi
Kazunori Suzuki
Shigeru Nishizawa
Takehiko Ohzeki
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Child's Nervous System / Issue 4/2007
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-006-0282-5

Other articles of this Issue 4/2007

Child's Nervous System 4/2007 Go to the issue

Case Report

Surgical treatment of polymicrogyria with advanced radiologic and neurophysiologic techniques

Case Report

Restricted diffusion in Canavan disease

Original Paper

Dynamic morphological changes in lumbosacral lipoma during the first months of life revealed by constructive interference in steady-state (CISS) MR imaging

Cover Picture

Gargoyle-like features in lysosomal diseases involving glycosaminoglycans

Original Paper

Pituitary tumors in children: clinical analysis of 21 cases

Case Report

Neonatal cavernous angioma located in the basal ganglia with profuse intraoperative bleeding